These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30979721)

  • 21. CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.
    Sonanini D; Schwenck J; Blaess S; Schmitt J; Maurer A; Ehrlichmann W; Ritter M; Skokowa J; Kneilling M; Jung G; Fend F; Krost S; Seitz CM; Lang P; Reischl G; Handgretinger R; Fougère C; Pichler BJ
    Biomark Res; 2024 May; 12(1):50. PubMed ID: 38735945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation.
    Feng H; Stachura DL; White RM; Gutierrez A; Zhang L; Sanda T; Jette CA; Testa JR; Neuberg DS; Langenau DM; Kutok JL; Zon LI; Traver D; Fleming MD; Kanki JP; Look AT
    Cancer Cell; 2024 Jun; 42(6):1130-1131. PubMed ID: 38861925
    [No Abstract]   [Full Text] [Related]  

  • 23. Combinatorial CAR design improves target restriction.
    Köksal H; Dillard P; Juzeniene A; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
    J Biol Chem; 2021; 296():100116. PubMed ID: 33234592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuning the Antigen Density Requirement for CAR T-cell Activity.
    Majzner RG; Rietberg SP; Sotillo E; Dong R; Vachharajani VT; Labanieh L; Myklebust JH; Kadapakkam M; Weber EW; Tousley AM; Richards RM; Heitzeneder S; Nguyen SM; Wiebking V; Theruvath J; Lynn RC; Xu P; Dunn AR; Vale RD; Mackall CL
    Cancer Discov; 2020 May; 10(5):702-723. PubMed ID: 32193224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.
    Golubovskaya V; Zhou H; Li F; Valentine M; Sun J; Berahovich R; Xu S; Quintanilla M; Ma MC; Sienkiewicz J; Huang Y; Wu L
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33652767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
    Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
    J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.
    Anderson GSF; Chapman MA
    Mol Ther; 2024 Sep; 32(9):2856-2891. PubMed ID: 39095991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?
    Mohty R; Alotaibi S; Gadd M; Luo Y; Parrondo R; Qin H; Kharfan-Dabaja MA
    Clin Hematol Int; 2023; 5(4):33-46. PubMed ID: 38817957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
    Pang Y; Ghosh N
    Front Oncol; 2024; 14():1396395. PubMed ID: 38711850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
    Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA-Based Therapeutic Technology.
    Mashima R; Takada S; Miyamoto Y
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of CAR T cell metabolism in an optimized protocol.
    Joaquina S; Forcados C; Caulier B; Inderberg EM; Wälchli S
    Front Bioeng Biotechnol; 2023; 11():1207576. PubMed ID: 37409169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies.
    Aranda-Orgilles B; Chion-Sotinel I; Skinner J; Grudman S; Mumford B; Dixon C; Postigo Fernandez J; Erler P; Duchateau P; Gouble A; Galetto R; Poirot L
    Cancer Immunol Res; 2023 Jul; 11(7):946-961. PubMed ID: 37257169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies.
    Kubacz M; Kusowska A; Winiarska M; Bobrowicz M
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
    Marhelava K; Krawczyk M; Firczuk M; Fidyt K
    Cells; 2022 May; 11(11):. PubMed ID: 35681499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of CAR T Cell Therapy in Children-A Comprehensive Overview.
    Boettcher M; Joechner A; Li Z; Yang SF; Schlegel P
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456250
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Xin T; Cheng L; Zhou C; Zhao Y; Hu Z; Wu X
    Front Oncol; 2022; 12():809754. PubMed ID: 35223491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.